Ceftriaxone

Generic Name: Ceftriaxone

Brand Names: Rocephin

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₈N_₈O_₇S_₃

CAS Number: 73384-59-5

Unique Ingredient Identifier: 75J73V1629

Background: Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.

Indication: Ceftriaxone is used for the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by susceptible organisms. Organisms that are generally susceptible to ceftriaxone include S. pneumoniae, S. pyogenes (group A beta-hemolytic streptococci), coagulase-negative staphylococci, Some Enterobacter spp, H. influenzae, N. gonorrhoeae, P. mirabilis, E. coli, Klebsiella spp, M. catarrhalis, B. burgdorferi, and some oral anaerobes.

Associated Conditions: Abscess Brain, Bacterial Endocarditis, Bacterial Infections, Bacterial Sinusitis, Bone and Joint Infections, Chancroid, Community Acquired Pneumonia (CAP), Conjunctivitis gonococcal neonatal, Epididymitis, Epiglottitis, Gonococcal arthritis, Gonococcal infection of pharynx, Gonococcal pelvic inflammatory disease, Intraabdominal Infections, Lower respiratory tract infection bacterial, Lyme Neuroborreliosis, Meningitis, Bacterial, Ophthalmia neonatorum due to gonococcus, Postoperative Infections, Prosthetic Joint Infections, Sepsis Bacterial, Septic Arthritis, Shigellosis, Skin and Subcutaneous Tissue Bacterial Infections, Syphilis, Vulvovaginitis gonococcal, Whipple Disease, Bacterial otitis media, Complicated Urinary Tract Infection caused by susceptible bacteria, Disease caused by Salmonella typhi, Susceptible Bacterial Infections, Uncomplicated Gonorrhea, Uncomplicated Urinary tract infection bacterial

Clinical Trials

Risk Factors of Failure of Conservative Treatment in Acute Non Complicated Appendicitis

Not yet recruiting

Conditions: Conservative Management

Interventions: Drug: ceftriaxone
Drug: ceftriaxone 1 gm/12 hourly and IV metronidazole 500 mg/8 hourly

First Posted Date: 2025-02-17

Last Posted Date: 2025-02-17

Lead Sponsor: Ahmed Mohammed Hussein Sayed

Target Recruit Count: 100

Registration Number: NCT06828952

Locations: 🇪🇬
Assiut University, Assuit, Egypt

Ceftriaxone for Post-Treatment Lyme Disease

Phase 1

Not yet recruiting

Conditions: Post-Treatment Lyme Disease Syndrome

Interventions: Drug: Ceftriaxone treatment
Drug: Placebo

First Posted Date: 2025-01-21

Last Posted Date: 2025-04-29

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 20

Registration Number: NCT06785402

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease

Early Phase 1

Recruiting

Conditions: Post-Treatment Lyme Disease

Interventions: Drug: Dextrose 5% (D5W)
Drug: Ceftriaxone (Rocephin®)

First Posted Date: 2024-09-24

Last Posted Date: 2025-02-14

Lead Sponsor: State University of New York - Upstate Medical University

Target Recruit Count: 44

Registration Number: NCT06611111

Locations: 🇺🇸
SUNY Upstate Medical University, Upstate Global Health Institute, East Syracuse, New York, United States

Comparison of Efficacy of Oral Amoxicillin Versus Intravenous Ceftriaxone

Not Applicable

Not yet recruiting

Conditions: Community-acquired Pneumonia

Interventions: Drug: IV ceftriaxone
Drug: Amoxicillin/CA

First Posted Date: 2024-08-01

Last Posted Date: 2024-08-01

Lead Sponsor: RESnTEC, Institute of Research

Target Recruit Count: 114

Registration Number: NCT06532409

Locations: 🇵🇰
Children Hospital, Lahore, Punjab, Pakistan

Prophylactic Antibiotic in Subtalar Fusion Surgery

Phase 2

Not yet recruiting

Conditions: Surgical Site Infection

Interventions: Drug: Ceftriaxone 2000 mg

First Posted Date: 2024-07-30

Last Posted Date: 2024-07-30

Lead Sponsor: Assiut University

Target Recruit Count: 102

Registration Number: NCT06527989

Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

Phase 4

Recruiting

Conditions: Community Acquired Pneumonia in Children

Interventions: Drug: Ampicillin for Injection
Drug: Ceftriaxone for Injection
Drug: Amoxicillin
Drug: Ampicillin / Sulbactam Injection
Drug: Amoxicillin-clavulanate
Drug: Clindamycin
Drug: Cefprozil
Drug: Levofloxacin

First Posted Date: 2024-07-10

Last Posted Date: 2024-11-20

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 236

Registration Number: NCT06494072

Locations: 🇺🇸
Childrens Wisconsin, Milwaukee, Wisconsin, United States

Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)

Phase 4

Recruiting

Conditions: Pregnancy, High Risk
Preterm Birth
Preterm Premature Rupture of Membrane

Interventions: Drug: Ampicillin 2 GM Injection
Drug: Ceftriaxone 1000 MG
Drug: Clarithromycin 500mg
Drug: Amoxicillin 250 MG
Drug: Metronidazole 500 mg
Drug: Azithromycin
Drug: Erythromycin

First Posted Date: 2024-05-02

Last Posted Date: 2024-07-29

Lead Sponsor: Ohio State University

Target Recruit Count: 56

Registration Number: NCT06396078

Locations: 🇺🇸
The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine, Columbus, Ohio, United States

Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth

Phase 4

Not yet recruiting

Conditions: Bacterial Vaginosis
Vaginal Dysbiosis
Premature Delivery

Interventions: Diagnostic Test: Vaginal flora abnormalities screening and quantification using molecular biology technique
Other: Usual Care
Drug: Azithromycine
Drug: Ceftriaxone
Drug: Metronidazole
Drug: Clotrimazole, Vaginal